Clinical Trials Browser

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Phase 1 Recruiting

246 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05176483 2026-03-12

STELLAR-002

Phase 1 Recruiting

1,314 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

36 enrolled

Dermatologic

Melanoma

NCT05536141 2026-02-27

ARC-20

Phase 1 Recruiting

362 enrolled

Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

33 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1 Recruiting

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06968988 2026-01-08

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Phase 1 Recruiting

18 enrolled

Sarcoma

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Phase 1 Recruiting

36 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Phase 1 Recruiting

56 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT07134842 2025-08-21

WinGlio-ipi

Phase 1 Recruiting

16 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Phase 1 Recruiting

12 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT04003649 2025-07-10

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Phase 1 Recruiting

60 enrolled

CNS

Glioblastoma

NCT04823403 2024-07-26

HIPANIV

Phase 1 Recruiting

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06514651 2024-07-23

MAQ-001 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

30 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06399419 2024-05-30

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Phase 1 Recruiting

28 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Phase 1 Recruiting

10 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

Clinical Trials

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

STELLAR-002

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

ARC-20

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

WinGlio-ipi

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

HIPANIV

MAQ-001 in Patients With Advanced Solid Tumors

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors